Leerink Partnrs Decreases Earnings Estimates for Certara

Key Points

• Leerink Partners has revised down its FY2025 earnings per share estimate for Certara, Inc. from $0.28 to $0.27.
• Certara reported a quarterly earnings miss of $0.07 per share, falling short of the consensus estimate of $0.10, even though revenue increased by 12.1% year-over-year.
• Analysts' ratings on Certara are mixed, with six analysts giving a Buy rating and an average target price of $15.63.

Certara, Inc. (NASDAQ:CERT - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Certara in a note issued to investors on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $0.27 for the year, down from their prior estimate of $0.28. The consensus estimate for Certara's current full-year earnings is $0.28 per share.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.57 million during the quarter, compared to analysts' expectations of $104.14 million. During the same period in the previous year, the company earned $0.07 earnings per share. Certara's revenue for the quarter was up 12.1% on a year-over-year basis.

A number of other research analysts also recently weighed in on CERT. Zacks Research raised Certara from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. Morgan Stanley began coverage on Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price for the company. UBS Group cut their target price on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Barclays increased their target price on Certara from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Finally, KeyCorp increased their target price on Certara from $15.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $15.63.

Certara Trading Up 0.5%

Shares of NASDAQ:CERT opened at $13.00 on Thursday. Certara has a 1 year low of $8.64 and a 1 year high of $15.69. The stock's fifty day moving average price is $11.23 and its 200-day moving average price is $11.39. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.16 and a quick ratio of 2.16. The company has a market cap of $2.09 billion, a P/E ratio of 260.05 and a beta of 1.45.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the transaction, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. The trade was a 40.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.33% of the company's stock.

Hedge Funds Weigh In On Certara

Institutional investors and hedge funds have recently modified their holdings of the stock. AdvisorNet Financial Inc purchased a new position in shares of Certara in the 2nd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Certara in the 1st quarter worth approximately $31,000. Osaic Holdings Inc. boosted its holdings in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after purchasing an additional 1,175 shares during the period. AlphaQuest LLC purchased a new position in shares of Certara in the 1st quarter worth approximately $39,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Certara in the 2nd quarter worth approximately $59,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.